抗NMDAR脑炎急性后期患者的临床特征:前瞻性队列研究及与精神分裂症谱系障碍患者的比较
这项前瞻性队列研究纳入了28例抗NMDAR脑炎急性后期患者,并与27例精神分裂症谱系障碍患者及27例健康对照比较,发现抗NMDAR脑炎患者急性后期认知精神症状与稳定期精神分裂症相似,但仅前者在12个月内逐渐改善,且改善主要发生于入组至6个月间。
要点
- 抗NMDAR脑炎急性后期认知精神症状与稳定期精神分裂症谱系障碍相似。
- 抗NMDAR脑炎患者认知精神症状在12个月内逐渐改善,主要发生于入组至6个月间。
- 意识下降及治疗前4周无改善可预测认知域结局。
核心结论
- 抗NMDAR脑炎急性后期认知精神症状与稳定期精神分裂症相似,但仅抗NMDAR脑炎患者逐渐改善,主要发生于入组至6个月间。
研究设计与样本
- 前瞻性队列研究,2017年1月1日至2020年9月30日在西班牙巴塞罗那Hospital Clínic de Barcelona招募82名12-60岁参与者,包括28例抗NMDAR脑炎急性后期患者、27例年龄匹配的精神分裂症谱系障碍患者和27例年龄性别匹配的健康对照,进行三次全面神经精神评估(入组V1、6个月V2、12个月V3),采用多水平线性混合效应模型分析组间及组内差异,调整组别、年龄、性别和社会经济地位。
主要发现
- 抗NMDAR脑炎患者急性期mRS中位评分5(IQR 4-5)vs V1时mRS中位评分2(IQR 1-2),p<0.0001;V1距发病中位4个月(IQR 3-7)。
- 抗NMDAR脑炎患者中25例(89%)在至少一个认知域存在缺陷;22个认知域变量中V1时15个(68%)受损,V3时仅8个(36%)异常,p=0.016。
- 精神分裂症谱系障碍患者22个变量中V1时11个(50%)受损,至V3无变化。
- 抗NMDAR脑炎患者所有精神症状群在V1时与精神分裂症谱系障碍患者相似改变,但仅抗NMDAR脑炎患者随后改善,p=0.031。
- 抗NMDAR脑炎患者中4例(14%)在V1至V2间期若未检测脑脊液抗体将符合精神分裂症诊断标准。
关键数值与推荐
- 急性期两个特征(意识下降和治疗前4周内无改善)预测认知域结局;V1时视空间任务(序列偏差)显示预测学习和记忆结局的潜力。
临床怎么用
- 作者认为这些发现对抗NMDAR脑炎临床试验重要,并建议及时认知心理社会康复可能是值得的干预。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-NMDA receptor (NMDAR) encephalitis is associated with a post-acute stage that is not well known. We aimed to describe the clinical features of this stage, similarities with schizophrenia spectrum disorders, and the factors that predict cognitive-psychiatric outcomes and could serve as prognostic biomarkers. METHODS: In this prospective cohort study, participants (aged 12-60 years) with anti-NMDAR encephalitis during the post-acute stage visited Hospital Clínic de Barcelona (Barcelona, Spain) on three occasions (at study entry [V1], at 6 months [V2], and at 12 months [V3]) and underwent comprehensive neuropsychiatric evaluations. Similar evaluations were done in a group of age-matched participants with schizophrenia spectrum disorders and a group of age-matched and sex-matched healthy participants also recruited from Hospital Clínic de Barcelona. We analysed differences between and within groups in the longitudinal follow-up using multilevel linear mixed-effect models, adjusting for group, age, sex, and socioeconomic status to control for possible confounding. FINDINGS: Between Jan 1, 2017, and Sept 30, 2020, 82 participants were recruited, 28 (34%) with anti-NMDAR encephalitis, 27 (33%) with schizophrenia spectrum disorders, and 27 (33%) healthy participants. Although, by V1 (median 4 months [IQR 3-7] from disease onset), many acute-stage symptoms in participants with anti-NMDAR encephalitis had resolved (acute stage median modified Rankin Scale [mRS] score 5 [IQR 4-5] vs V1 mRS score 2 [1-2]; p<0·0001), 25 (89%) participants showed deficits in at least one cognitive domain. In this group, 15 (68%) of 22 cognitive domain variables were impaired at V1, whereas only eight (36%) were altered at V3 (p=0·016). In participants with schizophrenia spectrum disorders, 11 (50%) of 22 variables (all shared with participants with anti-NMDAR encephalitis) were impaired at V1, without changes at V3. Two acute-stage features of anti-NMDAR encephalitis (ie, decreased consciousness and no improvement within the first 4 weeks of treatment) predicted cognitive domain outcomes, and a visuospatial task (ie, serial biases) at V1 showed potential in predicting learning and memory outcomes. At V1, all psychiatric symptom clusters were similarly altered in participants with anti-NMDAR encephalitis and in those with schizophrenia spectrum disorders, but only those in individuals with anti-NMDAR encephalitis subsequently improved (p=0·031). The greatest cognitive-psychiatric improvement in participants with anti-NMDAR encephalitis occurred between V1 and V2. During this interval, four (14%) participants with anti-NMDAR encephalitis would have met the diagnostic criteria of schizophrenia if CSF antibody findings had not been investigated. INTERPRETATION: The cognitive-psychiatric symptoms of anti-NMDAR encephalitis in the post-acute stage resembled those of stabilised schizophrenia, but only those in participants with anti-NMDAR encephalitis progressively improved, predominantly during V1-V2. These findings are important for clinical trials on anti-NMDAR encephalitis and suggest that prompt cognitive-psychosocial rehabilitation might be a valuable intervention. FUNDING: Instituto Salud Carlos III, NEURON Network of European Funding for Neuroscience Research, National Alliance for Research in Schizophrenia and Affective Disorders, and la Caixa Health-Research Foundation.
引用
- Guasp M, Rosa-Justicia M, Muñoz-Lopetegi A, et al. Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders. Lancet Neurol. 2022. PMID: 36115362. doi:10.1016/S1474-4422(22)00299-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。